title: Verapamil does not alter platelet function in patients with recent myocardial infarction.
abstract: Reports concerning the influence of the calcium antagonist verapamil on platelet function are conflicting. In a randomized double blind trial including 52 patients with acute myocardial infarction the effect of verapamil 120 mg given perorally three times a day for three months was investigated. There were no alterations in cutaneous bleeding time, platelet aggregate ratio or platelet aggregation induced by ADP or collagen. Verapamil administered in therapeutic doses does not seem to affect platelet function in patients with ischaemic heart disease.
mesh_terms: D000368:Aged; D001792:Blood Platelets / Q000187:drug effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood* / Q000188:drug therapy; D010974:Platelet Aggregation / Q000187:drug effects; D010979:Platelet Function Tests; D014700:Verapamil / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D014700:Verapamil